KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Short-term Investments (2017 - 2025)

Moderna (MRNA) has disclosed Short-term Investments for 9 consecutive years, with $3.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 37.15% to $3.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 billion, a 37.15% decrease, with the full-year FY2025 number at $3.2 billion, down 37.15% from a year prior.
  • Short-term Investments was $3.2 billion for Q4 2025 at Moderna, down from $3.4 billion in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $6.7 billion in Q4 2022 to a low of $2.3 billion in Q1 2021.
  • A 5-year average of $4.6 billion and a median of $4.5 billion in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: surged 325093.8% in 2021, then crashed 37.15% in 2025.
  • Moderna's Short-term Investments stood at $3.9 billion in 2021, then surged by 72.65% to $6.7 billion in 2022, then fell by 14.93% to $5.7 billion in 2023, then decreased by 10.51% to $5.1 billion in 2024, then crashed by 37.15% to $3.2 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Short-term Investments are $3.2 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.9 billion (Q2 2025).